Ovid Therapeutics reported progress in its clinical pipeline, including Phase 2 trials for OV329 targeting treatment-resistant focal epilepsy and developmental epileptic encephalopathies, with key data expected in 2027. The company is also advancing OV4071, a novel KCC2 activator, through Phase 1 trials and a ketamine challenge study, aiming to address multiple CNS disorders including psychosis. Financially, Ovid holds $161.4 million in cash and securities, supporting operations into 2029. Upcoming milestones include starting a pediatric study for TSC-associated seizures by year-end 2026 and further clinical data releases in early 2027, positioning Ovid for potential growth in neurological drug markets.
Ovid Therapeutics business updates provide context for readers following health stocks. For readers following health-sector US stocks on Pluang, here is the market snapshot as of Nov 10, 2026 17:51 WIB: Out of 150 stocks, 76 rose and 58 fell. Notable movers include RVTY at USD 163.35 with a 1.64% increase and 100% sell order activity, LFST at USD 14.81 up 1.44%, and MRNA at USD 272.82 with a 1.42% rise and balanced buy-sell activity.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
